TransMedics Group Quarterly Balance Sheets Chart
Quarterly
|
Annual
TransMedics Group Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-28 | 2019-09-28 | 2019-06-29 | 2019-03-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||
| cash | 400,575,000 | 310,143,000 | 336,650,000 | 330,094,000 | 362,751,000 | 350,217,000 | 394,812,000 | 427,110,000 | 582,210,000 | 195,375,000 | ||||||||||||||||
| accounts receivable | 104,851,000 | 142,026,000 | 97,722,000 | 90,128,000 | 81,158,000 | 81,942,000 | 63,576,000 | 60,654,000 | 47,524,000 | 38,620,000 | 27,611,000 | 22,035,000 | 12,979,000 | 11,724,000 | 5,934,000 | 4,150,000 | 6,271,000 | 7,395,000 | 6,864,000 | 6,141,000 | 4,431,000 | 6,133,000 | 7,105,000 | 5,146,000 | ||
| inventory | 38,868,000 | 43,380,000 | 46,554,000 | 52,152,000 | 48,671,000 | 48,541,000 | 44,235,000 | 39,365,000 | 30,545,000 | 23,961,000 | 20,605,000 | 18,575,000 | 17,468,000 | 16,714,000 | 14,859,000 | 14,869,000 | 13,007,000 | 11,820,000 | 11,934,000 | 12,984,000 | 12,555,000 | 11,361,000 | 11,216,000 | 10,536,000 | 11,220,000 | 11,294,000 |
| prepaid expenses and other current assets | 13,835,000 | 10,369,000 | 16,290,000 | 20,101,000 | 16,685,000 | 7,606,000 | 8,031,000 | 9,595,000 | 2,376,000 | 3,774,000 | 2,896,000 | 5,514,000 | 6,583,000 | 5,356,000 | 5,460,000 | 3,703,000 | 3,525,000 | 3,215,000 | 2,326,000 | 2,287,000 | 1,866,000 | 1,656,000 | 1,538,000 | 2,093,000 | 1,571,000 | 1,404,000 |
| total current assets | 558,129,000 | 505,918,000 | 497,216,000 | 492,475,000 | 509,265,000 | 488,306,000 | 510,654,000 | 536,724,000 | 662,655,000 | 261,730,000 | 252,294,000 | 250,586,000 | 95,113,000 | 105,795,000 | 118,705,000 | 125,577,000 | 135,052,000 | 140,543,000 | 146,766,000 | 154,126,000 | 158,227,000 | 91,704,000 | 100,001,000 | 107,366,000 | 116,133,000 | 30,059,000 |
| property, plant and equipment | 312,255,000 | 311,244,000 | 285,970,000 | 271,739,000 | 229,030,000 | 214,421,000 | 173,941,000 | 131,004,000 | ||||||||||||||||||
| operating lease right-of-use assets | 5,818,000 | 6,007,000 | 6,481,000 | 6,943,000 | 5,896,000 | 6,226,000 | 6,546,000 | 6,861,000 | 6,929,000 | 4,939,000 | 5,130,000 | 5,315,000 | 5,495,000 | 5,669,000 | 5,847,000 | |||||||||||
| restricted cash | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 750,000 | 750,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 | 500,000 |
| goodwill | 11,549,000 | 11,549,000 | 11,549,000 | 11,549,000 | 11,549,000 | 11,990,000 | 11,990,000 | 11,673,000 | ||||||||||||||||||
| acquired intangible assets | 2,050,000 | 2,101,000 | 2,152,000 | 2,202,000 | 2,253,000 | 2,303,000 | 2,354,000 | 2,405,000 | ||||||||||||||||||
| other non-current assets | 221,000 | 211,000 | 208,000 | 163,000 | 84,000 | 85,000 | 62,000 | 60,000 | 59,000 | 508,000 | ||||||||||||||||
| total assets | 890,522,000 | 837,530,000 | 804,076,000 | 785,571,000 | 758,577,000 | 723,831,000 | 706,047,000 | 689,227,000 | 690,358,000 | 287,088,000 | 277,147,000 | 274,873,000 | 117,285,000 | 124,008,000 | 134,893,000 | 131,146,000 | 140,512,000 | 145,783,000 | 152,026,000 | 159,322,000 | 163,137,000 | 96,923,000 | 105,299,000 | 112,618,000 | 121,014,000 | 38,759,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||
| accounts payable | 9,539,000 | 10,595,000 | 10,292,000 | 13,134,000 | 13,027,000 | 9,225,000 | 12,717,000 | 12,836,000 | 7,031,000 | 4,329,000 | 3,341,000 | 3,080,000 | 5,711,000 | 2,934,000 | 6,651,000 | 2,682,000 | 2,389,000 | 1,289,000 | 1,206,000 | 778,000 | 3,722,000 | 4,860,000 | 7,247,000 | 4,766,000 | 6,662,000 | 5,499,000 |
| accrued expenses and other current liabilities | 42,490,000 | 40,139,000 | 45,152,000 | 42,187,000 | 37,716,000 | 36,852,000 | 38,221,000 | 31,651,000 | 22,862,000 | 22,581,000 | 18,635,000 | 15,976,000 | 15,420,000 | 15,738,000 | 16,337,000 | 12,769,000 | 12,100,000 | 9,931,000 | 10,317,000 | 11,474,000 | 8,858,000 | 9,926,000 | 8,332,000 | 9,348,000 | 8,180,000 | 9,989,000 |
| deferred revenue | 1,570,000 | 2,078,000 | 1,742,000 | 2,184,000 | 1,447,000 | 2,060,000 | 1,961,000 | 2,629,000 | 244,000 | 244,000 | 241,000 | 226,000 | 238,000 | 247,000 | 250,000 | 320,000 | 473,000 | 432,000 | 263,000 | 1,347,000 | 1,020,000 | 164,000 | 166,000 | 162,000 | 175,000 | 359,000 |
| operating lease liabilities | 3,021,000 | 2,791,000 | 2,727,000 | 2,543,000 | 2,139,000 | 2,086,000 | 2,035,000 | 1,985,000 | 1,880,000 | 1,481,000 | 1,444,000 | 1,407,000 | 1,372,000 | 1,337,000 | ||||||||||||
| total current liabilities | 56,620,000 | 55,603,000 | 59,913,000 | 60,048,000 | 54,329,000 | 50,223,000 | 54,934,000 | 49,101,000 | 32,017,000 | 28,635,000 | 23,661,000 | 20,689,000 | 22,741,000 | 20,256,000 | 23,238,000 | 15,923,000 | 15,079,000 | 11,757,000 | 11,879,000 | 13,624,000 | 13,818,000 | 15,039,000 | 16,115,000 | 14,641,000 | 15,377,000 | 16,201,000 |
| convertible senior notes | 451,364,000 | 450,650,000 | 449,939,000 | 449,237,000 | 448,534,000 | 447,835,000 | 447,140,000 | 446,448,000 | 445,761,000 | |||||||||||||||||
| long-term debt | 59,525,000 | 59,448,000 | 59,372,000 | 59,294,000 | 59,217,000 | 59,141,000 | 59,064,000 | 58,986,000 | 58,908,000 | |||||||||||||||||
| operating lease liabilities, net of current portion | 4,912,000 | 5,521,000 | 6,249,000 | 7,072,000 | 6,603,000 | 7,161,000 | 7,707,000 | 8,232,000 | 8,459,000 | 7,026,000 | 7,415,000 | 7,787,000 | 8,150,000 | 8,508,000 | 8,604,000 | |||||||||||
| total liabilities | 572,421,000 | 571,222,000 | 575,473,000 | 575,651,000 | 568,683,000 | 564,360,000 | 568,845,000 | 562,767,000 | 545,145,000 | 94,463,000 | 89,772,000 | 87,016,000 | 66,366,000 | 64,098,000 | 67,039,000 | 52,597,000 | 51,529,000 | 48,108,000 | 48,135,000 | 49,772,000 | 49,377,000 | 50,240,000 | 50,650,000 | 49,146,000 | 49,853,000 | 51,278,000 |
| commitments and contingencies | ||||||||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||||||||
| preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding | ||||||||||||||||||||||||||
| common stock | 725,655,000 | 709,194,000 | 697,208,000 | 685,251,000 | 669,445,000 | 651,161,000 | 641,106,000 | 634,458,000 | 627,747,000 | 674,156,000 | 666,277,000 | 660,061,000 | 515,756,000 | 513,203,000 | 510,488,000 | 508,458,000 | 505,933,000 | 503,912,000 | 502,217,000 | 501,486,000 | 500,556,000 | 424,791,000 | 424,134,000 | 423,758,000 | 423,245,000 | 1,000 |
| accumulated other comprehensive income | 98,000 | 36,000 | 227,000 | -2,000 | 20,000 | |||||||||||||||||||||
| accumulated deficit | -407,652,000 | -442,559,000 | -468,241,000 | -475,098,000 | -479,314,000 | -491,508,000 | -503,705,000 | -507,736,000 | -482,314,000 | -481,313,000 | -478,677,000 | -471,957,000 | -464,531,000 | -453,008,000 | -442,446,000 | -429,778,000 | -416,816,000 | -406,148,000 | -398,231,000 | -391,920,000 | -386,832,000 | -378,335,000 | -369,483,000 | -360,306,000 | -352,026,000 | -342,831,000 |
| total stockholders' equity | 318,101,000 | 266,308,000 | 228,603,000 | 209,920,000 | 189,894,000 | 159,471,000 | 137,202,000 | 126,460,000 | 145,213,000 | 192,625,000 | 187,857,000 | 50,919,000 | 59,910,000 | 78,549,000 | 88,983,000 | 97,675,000 | 109,550,000 | 113,760,000 | ||||||||
| total liabilities and stockholders' equity | 890,522,000 | 837,530,000 | 804,076,000 | 785,571,000 | 758,577,000 | 723,831,000 | 706,047,000 | 689,227,000 | 690,358,000 | 287,088,000 | 274,873,000 | 117,285,000 | 124,008,000 | 131,146,000 | 140,512,000 | 145,783,000 | 159,322,000 | 163,137,000 | ||||||||
| accumulated other comprehensive loss | -327,000 | -364,000 | -233,000 | -237,000 | -182,000 | -199,000 | -262,000 | -220,000 | -218,000 | -225,000 | -247,000 | -306,000 | -285,000 | -188,000 | -131,000 | -134,000 | -89,000 | -95,000 | -16,000 | -58,000 | -67,000 | |||||
| property and equipment | 19,965,000 | 19,161,000 | 19,223,000 | 18,472,000 | 16,177,000 | 12,044,000 | 9,841,000 | 5,063,000 | 4,954,000 | 4,734,000 | 4,754,000 | 4,690,000 | 4,404,000 | 4,713,000 | 4,792,000 | 4,746,000 | 4,375,000 | 3,750,000 | ||||||||
| long-term debt, net of discount and current portion | 58,802,000 | 58,696,000 | 58,540,000 | 35,475,000 | 35,334,000 | 35,197,000 | 35,058,000 | 34,921,000 | 34,787,000 | 34,657,000 | 34,525,000 | 34,395,000 | 34,269,000 | 34,146,000 | ||||||||||||
| cash and cash equivalents | 201,182,000 | 204,462,000 | 30,386,000 | 17,897,000 | 25,580,000 | 22,495,000 | 25,314,000 | 26,727,000 | 24,581,000 | 21,397,000 | 51,152,000 | 24,738,000 | 20,092,000 | 20,407,000 | 47,242,000 | 12,215,000 | ||||||||||
| marketable securities | 27,697,000 | 54,104,000 | 66,872,000 | 80,360,000 | 86,935,000 | 91,386,000 | 101,061,000 | 111,317,000 | 88,223,000 | 47,816,000 | 60,596,000 | 67,865,000 | 48,995,000 | |||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||
| total stockholders’ equity | 187,375,000 | 67,854,000 | 103,891,000 | 46,683,000 | 54,649,000 | 63,472,000 | 71,161,000 | |||||||||||||||||||
| total liabilities and stockholders’ equity | 277,147,000 | 134,893,000 | 152,026,000 | 96,923,000 | ||||||||||||||||||||||
| other long-term assets | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | |||||||||||||||
| deferred rent, net of current portion | 1,616,000 | 1,529,000 | 1,564,000 | 1,599,000 | 1,623,000 | 1,164,000 | 932,000 | 389,000 | 482,000 | 574,000 | 667,000 | |||||||||||||||
| current portion of deferred rent | 152,000 | 117,000 | 105,000 | 93,000 | 25,000 | 218,000 | 89,000 | 370,000 | 365,000 | 360,000 | 354,000 | |||||||||||||||
| accounts receivable, net of 0 allowance | 6,559,000 | 6,465,000 | ||||||||||||||||||||||||
| deferred offering costs | 4,444,000 | |||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ deficit | ||||||||||||||||||||||||||
| preferred stock warrant liability | 625,000 | |||||||||||||||||||||||||
| convertible preferred stock (series a-1, b, b-1, c, d, e and f) 0.0001 par value; no shares and 50,776,054 shares authorized at december 28, 2019 and december 29, 2018, respectively; and no shares and 50,404,140 shares issued and outstanding at december 28, 2019 and december 29, 2018, respectively | ||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||
| preferred stock, no par value; 25,000,000 shares and no shares authorized at december 28, 2019 and december 29, 2018, respectively; no shares issued and outstanding at december 28, 2019 and december 29, 2018 | ||||||||||||||||||||||||||
| additional paid-in capital | 143,859,000 | |||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 105,299,000 | 112,618,000 | 121,014,000 | |||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||||
| long-term debt, net of discount | 34,023,000 | 33,902,000 | 33,785,000 | |||||||||||||||||||||||
| convertible preferred stock (series a-1, b, b-1, c, d, e and f) 0.0001 par value; no shares and 50,776,054 shares authorized at september 28, 2019 and december 29, 2018, respectively; and no shares and 50,404,140 shares issued and outstanding at september 28, 2019 and december 29, 2018, respectively | ||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||
| preferred stock, no par value; 25,000,000 shares and no shares authorized at september 28, 2019 and december 29, 2018, respectively; no shares issued and outstanding at september 28, 2019 and december 29, 2018 | ||||||||||||||||||||||||||
| preferred stock, no par value; 25,000,000 shares authorized at june 29, 2019; none issued and outstanding at june 29, 2019 | ||||||||||||||||||||||||||
| convertible preferred stock (series a-1, b, b-1, c, d, e and f) 0.0001 par value; 50,776,054 shares authorized at december 29, 2018; 50,404,140 shares issued and outstanding at december 29, 2018 | ||||||||||||||||||||||||||
| convertible preferred stock (series a-1, b, b-1, c, d, e and f), 0.0001 par value; 50,776,054 shares authorized at march 30, 2019 and december 29, 2018; 50,404,140 shares issued and outstanding at march 30, 2019 and december 29, 2018; aggregate liquidation preference of 223,681 at march 30, 2019 | 186,519,000 | |||||||||||||||||||||||||
| total stockholders’ deficit | -199,038,000 | |||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ deficit | 38,759,000 | |||||||||||||||||||||||||
| net revenue | 4,676,000 | |||||||||||||||||||||||||
| cost of revenue | 2,103,000 | |||||||||||||||||||||||||
| gross profit | 2,573,000 | |||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||
| research, development and clinical trials | 3,882,000 | |||||||||||||||||||||||||
| selling, general and administrative | 4,653,000 | |||||||||||||||||||||||||
| total operating expenses | 8,535,000 | |||||||||||||||||||||||||
| income from operations | -5,962,000 | |||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||
| interest expense | -1,093,000 | |||||||||||||||||||||||||
| change in fair value of preferred stock warrant liability | 273,000 | |||||||||||||||||||||||||
| other income | -103,000 | |||||||||||||||||||||||||
| total other income | -923,000 | |||||||||||||||||||||||||
| income before income taxes | -6,885,000 | |||||||||||||||||||||||||
| benefit from income taxes | -10,000 | |||||||||||||||||||||||||
| net income | -6,895,000 | |||||||||||||||||||||||||
| net income per share | -4,860 | |||||||||||||||||||||||||
| weighted-average common shares outstanding, basic and diluted | 1,418,353,000 |
We provide you with 20 years of balance sheets for TransMedics Group stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TransMedics Group. Explore the full financial landscape of TransMedics Group stock with our expertly curated balance sheets.
The information provided in this report about TransMedics Group stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.